A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

NCT04017832 on ClinicalTrials.gov · last registry update 2024-10-01

An unusually large phase 3: 1,441 participants, more than double the 424 typical for the stage. The sponsor logged completion for 27 October 2021. Primary outcome, as filed: Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,441
Started: 2019-07-29
Primary completion: 2021-10-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.